The Proportion of Dietary Salt Replaced with Potassium-Enriched Salt in the SSaSS: Implications for Scale-Up
Loading...
Date
Authors
Yin, Xuejun
Paige, Ellie
Tian, Maoyi
Li, Qiang
Huang, Liping
Yu, Jie
Rodgers, Anthony
Elliott, Paul
Wu, Yangfeng
Neal, Bruce
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams & Wilkins
Abstract
Background:
The SSaSS (Salt Substitute and Stroke Study) recently reported definitive effects of a potassium-enriched salt on cardiovascular outcomes and death. Quantifying the amount of potassium-enriched salt used by trial participants is important for understanding the magnitude of the effect of potassium-enriched salt on risk reduction and how population-wide scale-up might be achieved.
Methods:
Baseline and annual 24-hour urine samples were collected from subgroups of participants in SSaSS throughout the 5-year follow-up. The mean difference in 24-hour potassium excretion between the 2 groups was used to estimate the quantity of potassium-enriched salt consumed in the intervention group. The corresponding projected difference in sodium intake between groups was calculated and compared with the observed difference.
Results:
The potassium-enriched salt group, compared to the regular salt group, had a mean increase in 24-hour urinary potassium excretion of 0.80 g/d (95% CI, 0.71–0.90), which equates to consumption of 8.8 g/d (95% CI, 7.8–9.9) of potassium-enriched salt. Based on 8.8 g/d potassium-enriched salt consumption, the projected difference in 24-hour urinary sodium excretion was −0.79 g/d. This compares to an observed difference of −0.35 g/d (95% CI, −0.55 to −0.15) and suggests that 72% of baseline regular salt intake was replaced by potassium-enriched salt.
Conclusions:
The smaller than anticipated between-group difference in sodium excretion likely results from the joint use of regular salt and potassium-enriched salt in the intervention group. Our findings suggest that even an incomplete replacement of regular salt with potassium-enriched salt can deliver significant health gains.
Registration:
URL: https://www.clinicaltrials.gov; Unique identifier: NCT02092090.
Description
Citation
Collections
Source
Hypertension
Type
Book Title
Entity type
Access Statement
License Rights
Restricted until
2099-12-31